Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
MODI-1 + pembrolizumab
- Development stage
- Unknown
- Lead developer
- Scancell Holdings
- Modality
- Vaccines & Immunotherapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Intradermal, Intravenous
01
Overview
MODI-1 + pembrolizumab is an investigational combination regimen consisting of MODI-1, a peptide-based cancer vaccine, and pembrolizumab, a monoclonal antibody checkpoint inhibitor targeting PD-1. MODI-1 is composed of citrullinated and homocitrullinated peptides designed to stimulate an anti-tumor immune response. Pembrolizumab blocks the PD-1 receptor, enhancing T-cell mediated immune responses against tumors. The combination aims to leverage MODI-1's vaccine-driven T-cell activation alongside checkpoint inhibition by pembrolizumab, potentially improving immune recognition and destruction of cancer cells. The regimen is currently being investigated primarily for solid tumors including head and neck cancer, renal cancer, and triple negative breast cancer[5].
02
Targets
PDCD1 (Programmed cell death protein 1 receptor)
Beyond the preview
Go deeper on MODI-1 + pembrolizumab.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on MODI-1 + pembrolizumab.